A multicenter phase I/II study of irinotecan (CPT-11) and S-1 combination chemotherapy for metastatic colorectal cancer (CRC)

ABSTRACT: Interventions: Irinotecan+S-1, repeated every 3 weeks. Primary outcome(s): Phase I : recommended dose Phase I I: Response rate Study Design: Single arm Non-randomized

DISEASE(S): Advanced/recurrent Colorectal Cancer

PROVIDER: 2617107 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR